Eli Lilly (LLY) Shares Fall Over 15% in May

The share price of Eli Lilly and Company (LLY), the world’s largest pharmaceutical company, has seen a sharp shift in market sentiment:

→ From its April low to high, LLY shares rose by over 30%;
→ However, since the start of May, the LLY stock price has dropped more than 15% — the closing price on the last trading day of April was around $895, while today the share is trading near $775.

Why Are Eli Lilly (LLY) Shares Falling?

The decline can be attributed to three key factors:

1→ Q1 Earnings Report: Although the company reported earnings per share above expectations ($3.34 vs $3.25), investors may have been concerned by significantly higher spending on research and development.

2→ Competitor Partnership: CVS Health’s announcement that it will offer Novo Nordisk’s Wegovy instead of Lilly’s Zepbound added further pressure to LLY shares.

3→ Sector Sentiment: Broader biotech sentiment turned negative following reports that the Trump administration is considering a pricing model that would cap drug prices based on lower rates in other countries.

The media is also discussing upcoming decisions from Vinay Prasad, the new head of the FDA division overseeing vaccines and gene therapy.

Technical Analysis: Eli Lilly (LLY) Share Chart

Key price movements (marked on the chart) justify the formation of a downward channel.

On the one hand, bearish sentiment may intensify in light of recent developments. The median line of the channel could act as resistance to any upward movement.

On the other hand, bulls may find support around the $765 level — a former resistance point and the boundary between two price gaps.

Buy and sell stocks of the world's biggest publicly-listed companies with CFDs on FXOpen’s trading platform. Open your FXOpen account now or learn more about trading share CFDs with FXOpen.

This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.